Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1644
This examiner grants 56% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18407331 | METHODS FOR REDUCING OR ELIMINATING THE NEED FOR LIPOPROTEIN APHERESIS IN PATIENTS WITH HYPERLIPIDEMIA BY ADMINISTERING ALIROCUMAB | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 19285781 | COMPOSITIONS AND METHODS OF TREATING LUPUS NEPHRITIS | Non-Final OA | Genentech, Inc. |
| 17011433 | METHODS OF TREATING OR PREVENTING CHOLESTEROL RELATED DISORDERS | Final Rejection | Amgen Inc. |
| 14316587 | METHODS FOR TREATING HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | Final Rejection | AMGEN INC. |
| 13931716 | METHODS FOR TREATING OR PREVENTING CHOLESTEROL RELATED DISORDERS | Final Rejection | AMGEN INC. |
| 19213363 | COMPOSITIONS FOR IMPROVING KIDNEY FUNCTION IN PATIENTS WITH HEPATORENAL SYNDROME | Final Rejection | Mallinckrodt Pharmaceuticals Ireland Limited |
| 18416231 | COMPOSITIONS FOR IMPROVING KIDNEY FUNCTION IN PATIENTS WITH HEPATORENAL SYNDROME | Non-Final OA | Mallinckrodt Pharmaceuticals Ireland Limited |
| 18021912 | CONFORMATION-SPECIFIC ANTIBODIES THAT BIND TAU PROTEIN AND USES THEREOF | Non-Final OA | Beth Israel Deaconess Medical Center, Inc. |
| 17709770 | METHOD FOR IMPROVING AFFINITY OF ANTIBODY FOR ANTIGEN AND USE THEREOF | Final Rejection | SYSMEX CORPORATION |
| 17686624 | METHODS OF PERMITTING A SUBJECT TO RECEIVE MULTIPLE DOSES OF RECOMBINANT ADENO-ASSOCIATED VIRUS | Final Rejection | University of Florida Research Foundation, Incorporated |
| 18262843 | ADJUVANT THERAPY FOR CANCER | Non-Final OA | Iovance Biotherapeutics, Inc. |
| 18888316 | METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | Non-Final OA | Tourmaline Bio, Inc. |
| 18523203 | ANTIBODIES SPECIFICALLY BINDING TO MASP-3 FOR THE TREATMENT OF VARIOUS DISEASES AND DISORDERS | Non-Final OA | Omeros Corporation |
| 17626616 | TREATMENT OF DISEASES ASSOCIATED WITH PROTEIN MISFOLDING BY NERVOUS SYSTEM EXPRESSION OF AN ENZYME WHICH HAS A DEOXYRIBONUCLEASE (DNase) ACTIVITY | Final Rejection | CLS THERAPEUTICS LIMITED |
| 18267561 | HER2 ANTIBODY AND APPLICATION THEREOF | Non-Final OA | SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. |
| 18189712 | Methods and Compositions for the Treatment of Celiac Disease, Non-Celiac Gluten Sensitivity, and Refractory Celiac Disease | Non-Final OA | Celimmune LLC |
| 18094151 | LIGHT INHIBITORS FOR SCLERODERMA AND SKIN FIBROTIC DISEASE TREATMENT | Final Rejection | La Jolla Institute for Allergy and Immunology |
| 18058843 | ANTI-TMPRSS6 ANTIBODIES AND USES THEREOF | Non-Final OA | MABWELL THERAPEUTICS, INC. |
| 17984611 | DPP3 BINDER DIRECTED TO AND BINDING TO SPECIFIC DPP3-EPITOPES AND ITS USE IN THE PREVENTION OR TREATMENT OF DISEASES/ACUTE CONDITIONS THAT ARE ASSOCIATED WITH OXIDATIVE STRESS | Non-Final OA | 4TEEN4 Pharmaceuticals GmbH |
| 17310459 | TREATMENT INVOLVING CAR-ENGINEERED T CELLS AND CYTOKINES | Final Rejection | BIONTECH CELL & GENE THERAPIES GMBH |
| 17817539 | ANTI-HEPSIN ANTIBODIES AND USES THEREOF | Non-Final OA | Navaux, Inc. |
| 17841326 | ENGINEERED ANTIBODIES AND METHODS OF TREATMENT | Non-Final OA | Tiga TX, Inc. |
| 17743177 | ANTIBODIES SPECIFIC FOR HUMAN ALPHA-SYNUCLEIN FOR TREATING ALPHA-SYNUCLEINOPATHIES | Non-Final OA | ABL BIO INCORPORATED |
| 17776295 | ANTI-PCSK9 ANTIBODY AND USE THEREOF | Non-Final OA | AD Pharmaceuticals Co., Ltd. |
| 17596958 | INHIBITOR OF SURFACE PROTEIN (SP-D) / SIRPA / SHP2 PATHWAY FOR USE IN THE PREVENTION AND/OR TREATMENT OF SECONDARY INFECTION | Final Rejection | CHU DE NANTES - CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy